We therefore analyzed published histone ChIP-seq data that provided epigenomic profiling of several NB cell lines, both MYCN-amplified and MYCN-non-amplified.28 The data set included ChIP-seq for the repressive histone mark H3K27me3 as well as for activating histone marks (H3K27Ac, H3K4me3), whereas H3K9me2 was not assessed in this study. The gene discussed is MYCN; the disease is neuroblastoma.